Cogent Biosciences Q3 2020 Earnings Report
Key Takeaways
Cogent Biosciences reported collaboration revenue of $0.3 million and a net loss of $50.0 million for the third quarter ended September 30, 2020. The company ended the quarter with $129.4 million in cash and cash equivalents.
Andrew Robbins was appointed President, CEO and Director.
Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients were selected for oral presentation at CTOS 2020 meeting.
The company completed Kiq LLC acquisition, gaining global rights to PLX9486.
Cogent Biosciences completed a $104.4M Series A preferred stock private placement.
Cogent Biosciences
Cogent Biosciences
Cogent Biosciences Revenue by Segment
Forward Guidance
This press release contains forward-looking statements regarding projected cash runways, future product development plans, upcoming results from clinical trials including from its lead program, PLX9486, and any future payouts under the CVR.